The approval of fibrinogen (human) lyophilized powder for reconstitution (Fibryga, Octapharma) has been expanded by the FDA with a new indication for fibrinogen replacement in bleeding patients with acquired fibrinogen deficiency (AFD), according to the company.
Fibryga is the only on-demand, virus-inactivated, human plasma–derived fibrinogen concentrate option with this approval. It can be stored at room temperature or refrigerated since it’s a lyophilized powder and quickly